US Appeals Court Denies Genentech Injunction Over Amgen's 'At Risk' Trastuzumab Launch
Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.
You may also be interested in...
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
By weakening ways to challenge drug patent thickets, proposed legislation to reform US patent law would extend brand monopolies and increase spending on medicines, the Association for Accessible Medicines is warning.
Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.